Ray B L, Painter G, Raetz C R
J Biol Chem. 1984 Apr 25;259(8):4852-9.
We have discovered an enzyme in the cytosol of Escherichia coli that generates lipid A disaccharides from monosaccharide precursors by the following route: 2,3-diacyl-GlcN-1-P + UDP-2,3-diacyl-GlcN---- 2,3-diacyl-GlcN (beta, 1----6) 2,3-diacyl-GlcN-1-P + UDP. Previous studies from our laboratory have documented the presence in vivo of the precursors 2,3-diacylglucosamine 1-phosphate (2,3-diacyl-GlcN-1-P) (lipid X of E. coli) and UDP-2,3-diacylglucosamine (UDP-2,3-diacyl-GlcN) (Bulawa, C.E., and Raetz, C.R.H.J. Biol. Chem. 259, 4846-4851). Both substrates are novel glucosamine-derived phospholipids, acylated with beta-hydroxymyristoyl moieties, and they accumulate in E. coli mutants defective in the pgsB gene. Synthetic ADP-, GDP-, and CDP-2,3-diacylglucosamines are inefficient substrates compared to the naturally occurring UDP derivative. The free-acid form of the tetraacyldisaccharide 1-phosphate product (C68H129N2O20P) that is generated in vitro has Mr = 1325.74 as judged by fast atom bombardment mass spectrometry. Mild acid hydrolysis (0.1 M HCl for 30 min at 100 degrees C) liberates greater than 95% of the phosphate moiety as Pi. Detailed analysis by 1H and 13C NMR spectroscopy confirms the presence of a phosphate residue at position 1 of the disaccharide, an alpha-anomeric configuration at the reducing end, and a beta, 1----6 linkage between the two glucosamines. Importantly the disaccharide 1-phosphate synthase is missing in extracts of E. coli strains harboring the pgsB1 mutation, consistent with the massive accumulation of 2,3-diacyl-GlcN-1-P and UDP-2,3-diacyl-GlcN in vivo. The enzymatic reaction reported here represents a major biosynthetic route for the formation of lipid A disaccharides in E. coli and other Gram-negative bacteria. An in vitro system for the biosynthesis of lipid A disaccharides has not been described previously.
我们在大肠杆菌的胞质溶胶中发现了一种酶,该酶可通过以下途径从单糖前体生成脂多糖A二糖:2,3-二酰基葡糖胺-1-磷酸 + UDP-2,3-二酰基葡糖胺→2,3-二酰基葡糖胺(β,1→6)2,3-二酰基葡糖胺-1-磷酸 + UDP。我们实验室之前的研究已证明,前体2,3-二酰基葡糖胺1-磷酸(2,3-二酰基-GlcN-1-P)(大肠杆菌的脂质X)和UDP-2,3-二酰基葡糖胺(UDP-2,3-二酰基-GlcN)在体内存在(Bulawa, C.E., and Raetz, C.R.H. J. Biol. Chem. 259, 4846 - 4851)。这两种底物都是新型的源自葡糖胺的磷脂,被β-羟基肉豆蔻酰基部分酰化,并且它们在pgsB基因缺陷的大肠杆菌突变体中积累。与天然存在的UDP衍生物相比,合成的ADP-、GDP-和CDP-2,3-二酰基葡糖胺是低效底物。通过快原子轰击质谱法判断,体外生成的四酰基二糖1-磷酸产物(C68H129N2O20P)的游离酸形式的Mr = 1325.74。温和酸水解(0.1 M HCl在100℃下处理30分钟)可释放超过95%的磷酸基团作为无机磷酸。通过1H和13C NMR光谱进行的详细分析证实,二糖的1位存在磷酸残基,还原端存在α-异头构型,并且两个葡糖胺之间存在β,1→6连接。重要的是,在携带pgsB1突变的大肠杆菌菌株的提取物中缺失二糖1-磷酸合酶,这与体内2,3-二酰基-GlcN-1-P和UDP-2,3-二酰基-GlcN的大量积累一致。此处报道的酶促反应代表了大肠杆菌和其他革兰氏阴性细菌中脂多糖A二糖形成的主要生物合成途径。此前尚未描述过用于脂多糖A二糖生物合成的体外系统。